CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR

DRUG4 trials

Sponsors

UZ Leuven, Centre Hospitalier Universitaire De Nimes, Assistance Publique Hopitaux De Paris

Conditions

Ceftazidime-avibactam therapy in critically ill patients undergoing continuous renal replacement therapyPyogenic liver abscessSerious infections in critically ill patients treated with antibioticsantibiotic therapy in Sepsis

Phase 3

BICCS - Beta-lactam Intermittent versus Continuous infusion and Combination antibiotic therapy in Sepsis

Not yet recruitingCTIS2024-516849-39-01

Assistance Publique Hopitaux De Parisantibiotic therapy in Sepsis

Target: 600Updated: 2025-12-02

Phase 4

Development of an optimized dosing regimen of ceftazidime-avibactam in critically ill patients treated with continuous renal replacement therapy

RecruitingCTIS2023-505536-35-00

UZ LeuvenCeftazidime-avibactam therapy in critically ill patients undergoing continuous renal replacement therapy

Start: 2025-05-04Target: 14Updated: 2025-02-04

TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial

Not yet recruitingCTIS2025-520940-14-00

Assistance Publique Hopitaux De ParisPyogenic liver abscess

Target: 456Updated: 2025-10-06

Defining Antibiotic Levels in Intensive care patients (DALI-2) protocol - A multi-national pharmacokinetic/pharmacodynamic cohort study to determine whether contemporary antibiotic dosing for critically ill patients achieves therapeutic exposures.

Not yet recruitingCTIS2024-516232-10-00

Centre Hospitalier Universitaire De NimesSerious infections in critically ill patients treated with antibiotics

Target: 200Updated: 2025-10-17